# A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis

> **NCT01272089** · PHASE4 · COMPLETED · sponsor: **Alcon Research** · enrollment: 300 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Olopatadine Hydrochloride Ophthalmic Solution, 0.2%

## Key facts

- **NCT ID:** NCT01272089
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2012-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01272089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01272089, "A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01272089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*